Phase III, open-label, randomized, multicenter study of ravulizumab in adult and adolescent patients with thrombotic microangiopathy (TMA) after hematopoietic stem cell transplantation (HSCT)
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ALEXION PHARMACEUTICALS, INC.
- Phase: III
- Execution start: 03/11/2020
- End of execution: 30/12/2025
- PI: PEDRO ANTONIO GONZALEZ SIERRA